標(biāo)題: Titlebook: Renal Cell Carcinoma; Clinical Management Steven C. Campbell,Brian I. Rini Book 2013 Springer Science+Business Media New York 2013 Familial [打印本頁(yè)] 作者: 深謀遠(yuǎn)慮 時(shí)間: 2025-3-21 18:07
書(shū)目名稱(chēng)Renal Cell Carcinoma影響因子(影響力)
作者: 極少 時(shí)間: 2025-3-22 00:15
Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways as well as what perturbations stemming from . loss or mutation can result in advanced RCC. Finally, we will touch on the immunologic monitoring of RCC and the opportunities related to manipulating the immune system for treating patients with advanced RCC.作者: 官僚統(tǒng)治 時(shí)間: 2025-3-22 01:44
Etiology of Renal Cell Carcinoma: Incidence, Demographics, and Environmental Factors environmental and lifestyle risk factors for renal cell carcinoma (RCC). A wide variability in geographic, gender, and ethnic differences has been observed relative to RCC around the world, with tobacco use, obesity, and hypertension emerging as the primary environmental factors that predispose to RCC.作者: 宏偉 時(shí)間: 2025-3-22 06:22 作者: Repatriate 時(shí)間: 2025-3-22 11:29
Integration of Surgery in Metastatic Renal Cancer the role of debulking cytoreductive nephrectomy (CN) and metastasectomy in mRCC. In addition, the concepts of treatment with a period of targeted therapy prior to CN (upfront therapy) have become a reality. This chapter will give an overview of the historical concepts and recent changes in surgical paradigms.作者: NATAL 時(shí)間: 2025-3-22 14:03
Prognostic Factors for Localized Renal Cell Carcinomafor more accurate counseling of patients regarding their likely clinical course, help to classify patients with greatest potential to benefit from adjuvant treatments, and facilitate ongoing cancer surveillance.作者: tackle 時(shí)間: 2025-3-22 18:24 作者: instill 時(shí)間: 2025-3-22 22:54 作者: accrete 時(shí)間: 2025-3-23 04:28 作者: Infelicity 時(shí)間: 2025-3-23 06:16
Book 2013 clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and作者: 泥土謙卑 時(shí)間: 2025-3-23 10:30 作者: Cardioplegia 時(shí)間: 2025-3-23 14:30
Pathology of Renal Cell Carcinomacells, are the most common renal tumors. They have distinct clinical, pathologic, and genetic characteristics as well as diverse prognosis and therapeutic responses. The 2004 World Health Organization classification of renal tumors represents the most updated classification system based primarily on作者: Spartan 時(shí)間: 2025-3-23 20:51 作者: 河流 時(shí)間: 2025-3-23 22:34
Imaging of Renal Cell Carcinoma (RCC). Imaging is considered essential in the management of RCC, not only for detection, but also for staging, surgical planning, guiding local ablative therapies, and assessing post-treatment response, including to targeted antiangiogenic therapy. In this chapter, we summarize the current status o作者: Chameleon 時(shí)間: 2025-3-24 04:54
Prognostic Factors for Localized Renal Cell Carcinomaill recur after initial treatment. Many clinical, histologic, and molecular factors have been identified that place patients with localized RCC at greater risk for recurrence or death. In this chapter, factors affecting RCC prognosis in patients with localized disease, including patient and tumor ch作者: Physiatrist 時(shí)間: 2025-3-24 08:49
Assessment of Oncologic Risk for Clinical Stage T1 Renal Tumors and the Emerging Role of Renal Mass operative complication and postoperative kidney dysfunction. This chapter is focused on recent data pertaining to the pathology and risk assessment of SRMs. In general the distribution of benign, indolent, and aggressive kidney tumors is 20%, 80%, and 20%, respectively. The mean rate of growth for S作者: infatuation 時(shí)間: 2025-3-24 13:20
Radical Nephrectomy for Localized Renal Tumors: Optimum Oncological and Renal Functional Consideratiincrease in the incidence and twofold increase in the mortality of renal cancer. Associated risk factors for kidney cancer include hypertension, obesity, and African American race. Epidemiological evidence suggests an increase in all stages of renal cancer, including the advanced and metastatic case作者: Flu表流動(dòng) 時(shí)間: 2025-3-24 18:10
Nephron-Sparing Surgery for Renal Cancerrenal tumors. The biological potential of these tumors tends to be more favorable than larger tumors. The surgical treatment paradigm for small localized renal tumors has shifted from radical nephrectomy to nephron-sparing surgery (NSS) with the goal of preserving long-term renal function without af作者: 高射炮 時(shí)間: 2025-3-24 19:01 作者: FIG 時(shí)間: 2025-3-24 23:18 作者: disciplined 時(shí)間: 2025-3-25 04:23
Locally Advanced Renal Cell Carcinomaisease, patients with locally advanced RCC, including venous involvement, extracapsular extension, and involvement of adjacent lymph nodes or organs, demonstrate a high risk for both recurrence and progression of disease with decreased survival despite surgical therapy. Regardless, aggressive surgic作者: 冬眠 時(shí)間: 2025-3-25 08:16 作者: 中國(guó)紀(jì)念碑 時(shí)間: 2025-3-25 13:53 作者: 舊病復(fù)發(fā) 時(shí)間: 2025-3-25 19:29
Prognostic Factors in Advanced Renal Cell Carcinomaes decision making for patients, physicians, and clinical trialists. Broadly, prognostic factors in this disease are related to patient factors, tumor burden, proinflammatory processes and treatment factors. Future prognostic models will need to incorporate biomarkers (yet to be determined) in addit作者: Sinus-Rhythm 時(shí)間: 2025-3-25 21:49
Integration of Surgery in Metastatic Renal Cancer(mRCC). The significant improvement in progression-free and overall survival and the reduction in the tumour volume have renewed the controversy about the role of debulking cytoreductive nephrectomy (CN) and metastasectomy in mRCC. In addition, the concepts of treatment with a period of targeted the作者: floaters 時(shí)間: 2025-3-26 02:41
Pathology of Renal Cell Carcinoma morphological features. Genetic characteristics have been increasingly incorporated into the clinically meaningful classification systems. Pathological examination of the renal neoplasm specimens not only renders an accurate diagnosis and classification but also provides information important for prognosis and therapeutic decisions.作者: INCUR 時(shí)間: 2025-3-26 07:30
Familial Renal Cell Carcinoma–Hogg–Dubè, and hereditary leiomyomatosis RCC. Each of these hereditary kidney cancer syndromes has distinct clinical manifestations and treatment challenges. In this context, our objective is to provide an overview of the molecular genetics, clinical syndromes, and management strategy of hereditary kidney cancer syndromes.作者: glowing 時(shí)間: 2025-3-26 08:31
Imaging of Renal Cell Carcinomaf imaging in each of these aspects and compare the strengths and weaknesses of computed tomography, magnetic resonance imaging, and ultrasound. The imaging features of different histologies of RCC and other solid renal masses are also discussed and illustrated.作者: micronutrients 時(shí)間: 2025-3-26 16:38
Thermal Ablationr prior partial nephrectomy, these represent situations where thermal ablation may have its best role. While newer energy modalities and delivery devices continue to be investigated, RFA and cryoablation continue to have the largest clinical experience and available data.作者: myelography 時(shí)間: 2025-3-26 18:49
Locally Advanced Renal Cell Carcinomaal resection, when feasible, remains the best treatment for locally advanced RCC. Although surgical management of locally advanced disease may be challenging, excellent results, including improved cancer-specific survival, can be achieved.作者: 字形刻痕 時(shí)間: 2025-3-27 00:44
Neoadjuvant Targeted Therapy and Consolidative Surgerycomes of nephron-sparing surgery for bulky or locally extensive tumors. Herein, we discuss patient selection criteria, assess the emerging data for this approach, and highlight perioperative patient safety concerns, arguments for and against utilization of primary systemic targeted therapy, and future directions for investigation.作者: Adjourn 時(shí)間: 2025-3-27 02:59 作者: 倔強(qiáng)一點(diǎn) 時(shí)間: 2025-3-27 05:49
Andrei S. Purysko MD,Erick M. Remer MD,Brian R. Herts MD作者: prolate 時(shí)間: 2025-3-27 10:27 作者: Basal-Ganglia 時(shí)間: 2025-3-27 16:26 作者: 不能和解 時(shí)間: 2025-3-27 20:51
Alon Z. Weizer MD, MS,Jeffery S. Montgomery MD, MHSA,Khaled S. Hafez MDtime-constructible function..Note that, if . is provable in AV-mathematics, then for each algorithm . it is provable that “. does not solve . or . does not work in polynomial time”. Interestingly, there exist algorithms for which it is neither provable that they do not work in polynomial time, nor t作者: CYN 時(shí)間: 2025-3-27 23:19 作者: 悲觀 時(shí)間: 2025-3-28 05:49
Marc C. Smaldone,Daniel Canter,Alexander Kutikov,Robert G. Uzzooperties of quasi-orders, we prove that . is just the family of . languages, even if the presence of edges is controlled by some arbitrary function of the time. In other words, we prove that, when waiting is allowed, the power of the accepting automaton drops drastically from being as powerful as a 作者: auxiliary 時(shí)間: 2025-3-28 07:45 作者: 有助于 時(shí)間: 2025-3-28 13:43
Stephen H. Culp,Christopher G. Woodcated distribution for truth values. We use the bound . and results on matching autarkies to obtain a new lower bound on the maximum number of clauses that can be satisfied by a truth assignment in any 3-satisfiable CNF formula..We use our results above to show that the following parameterized probl作者: Occlusion 時(shí)間: 2025-3-28 18:00 作者: 符合國(guó)情 時(shí)間: 2025-3-28 19:37 作者: Neutropenia 時(shí)間: 2025-3-29 01:00 作者: Kaleidoscope 時(shí)間: 2025-3-29 05:00
Radical Nephrectomy for Localized Renal Tumors: Optimum Oncological and Renal Functional Consideratid use of the modern abdominal imaging techniques (CT, MRI, and abdominal ultrasound) over the last two decades, usually ordered to evaluate nonspecific abdominal and musculoskeletal complaints or during unrelated cancer care, has changed the profile of the typical renal tumor patient from one with a作者: Lacunar-Stroke 時(shí)間: 2025-3-29 08:20 作者: 脆弱么 時(shí)間: 2025-3-29 11:25 作者: MENT 時(shí)間: 2025-3-29 18:27
Steven C. Campbell,Brian I. RiniComprehensive, state-of-the art review.Provides important advances in new surgical techniques.Provides advances in systemic treatments.Includes supplementary material: 作者: 脫落 時(shí)間: 2025-3-29 22:11 作者: 自傳 時(shí)間: 2025-3-30 01:05
Renal Cell Carcinoma978-1-62703-062-5Series ISSN 2197-7194 Series E-ISSN 2197-7208 作者: 多余 時(shí)間: 2025-3-30 08:06 作者: 外貌 時(shí)間: 2025-3-30 11:17
https://doi.org/10.1007/978-1-62703-062-5Familial RCC; Multiplanar CT; RAD Nx; Radiographic imaging; Targeted therapy; Thermal ablation; cT1 renal 作者: humectant 時(shí)間: 2025-3-30 14:46 作者: 歡樂(lè)中國(guó) 時(shí)間: 2025-3-30 19:33
Paul Russo MD, FACSl theory that enables to algorithmically verify for any given text whether it is a proof or not algorithmically verifiable mathematics (AV-mathematics for short). We say that a decision problem . is almost everywhere solvable if for all but finitely many inputs . one can prove either “.” or “.” in A作者: Introvert 時(shí)間: 2025-3-30 23:36
Alon Z. Weizer MD, MS,Jeffery S. Montgomery MD, MHSA,Khaled S. Hafez MDl theory that enables to algorithmically verify for any given text whether it is a proof or not algorithmically verifiable mathematics (AV-mathematics for short). We say that a decision problem . is almost everywhere solvable if for all but finitely many inputs . one can prove either “.” or “.” in A作者: 秘傳 時(shí)間: 2025-3-31 04:39
Surena F. Matin MD, FACS,Kamran Ahrar MDNP-hard optimization problems such as CLIQUE, COLORING, SET-COVER etc. is no easier than computing optimal solutions..After the above notable successes, this effort is now stuck for many other problems, such as METRIC TSP, VERTEX COVER, GRAPH EXPANSION, etc..In a recent paper with Béla Bollobás and 作者: Confirm 時(shí)間: 2025-3-31 06:30
Marc C. Smaldone,Daniel Canter,Alexander Kutikov,Robert G. Uzzo In these systems, a path from a node to another might still exist over time, rendering computing possible, even though at no time the path exists in its entirety. Some of these systems allow waiting (i.e., provide the nodes with store-carry-forward-like mechanisms such as local buffering) while oth作者: 跳動(dòng) 時(shí)間: 2025-3-31 09:23
